LifeMD, Inc. (NASDAQ:LFMD) Stock Has Consensus Target Price of $7.57 According to Analysts

LifeMD, Inc. (NASDAQ:LFMD) has been assigned a consensus rating of “Moderate Buy” from the ten analysts that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $7.57.

A number of research analysts have commented on the company. BTIG Research lowered their price target on LifeMD from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Wall Street Zen lowered LifeMD from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. B. Riley Financial initiated coverage on LifeMD in a research report on Friday, September 11th. They issued a “buy” rating and a $8.00 price objective on the stock. Lake Street Capital set a $5.00 target price on LifeMD in a research note on Thursday, August 6th. Finally, Mizuho set a $7.00 price target on LifeMD in a research note on Thursday, August 6th.

LifeMD Stock Up 2.2%

Shares of NASDAQ LFMD opened at $2.79 on Friday. The firm’s fifty day moving average is $3.21 and its 200 day moving average is $3.93. LifeMD has a 52 week low of $2.56 and a 52 week high of $6.82. The company has a market cap of $134.48 million, a price-to-earnings ratio of -55.79 and a beta of 1.99.

LifeMD (NASDAQ:LFMD) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.01). The firm had revenue of $47.28 million for the quarter, compared to the consensus estimate of $49.16 million. LifeMD had a net margin of 0.10% and a negative return on equity of 168.23%. Equities research analysts anticipate that LifeMD will post -0.48 earnings per share for the current year.

Institutional Investors Weigh In On LifeMD

Several institutional investors and hedge funds have recently modified their holdings of LFMD. Integrated Wealth Concepts LLC bought a new stake in shares of LifeMD during the 2nd quarter valued at about $25,000. R Squared Ltd bought a new position in LifeMD in the first quarter worth about $41,000. Corient Private Wealth LP bought a new position in LifeMD in the second quarter worth about $63,000. AXQ Capital LP purchased a new stake in LifeMD in the fourth quarter worth about $67,000. Finally, Quantbot Technologies LP purchased a new stake in LifeMD in the second quarter worth about $89,000. 35.52% of the stock is owned by hedge funds and other institutional investors.

LifeMD Company Profile

LifeMD, Inc is a U.S.-based telehealth company that provides virtual medical care through its digital health platform. The company connects patients with licensed health care professionals through online consultations and supports diagnosis, treatment, prescription management and ongoing care without requiring an in-person visit.

Its services include virtual primary care and programs focused on areas such as weight management, men’s and women’s health, dermatology and other common health needs.